Stem, Inc. (NYSE:STEM) Shares Bought by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund raised its position in Stem, Inc. (NYSE:STEMGet Rating) by 27.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 229,398 shares of the company’s stock after acquiring an additional 49,720 shares during the period. Healthcare of Ontario Pension Plan Trust Fund owned approximately 0.15% of Stem worth $1,642,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Principal Financial Group Inc. boosted its stake in Stem by 3.4% in the second quarter. Principal Financial Group Inc. now owns 21,593 shares of the company’s stock valued at $155,000 after acquiring an additional 719 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in shares of Stem by 4.3% during the second quarter. Advisors Asset Management Inc. now owns 32,261 shares of the company’s stock worth $231,000 after buying an additional 1,331 shares during the period. Commonwealth Equity Services LLC lifted its stake in shares of Stem by 3.9% during the second quarter. Commonwealth Equity Services LLC now owns 58,536 shares of the company’s stock worth $419,000 after buying an additional 2,197 shares during the period. California State Teachers Retirement System lifted its stake in shares of Stem by 2.5% during the first quarter. California State Teachers Retirement System now owns 92,032 shares of the company’s stock worth $1,013,000 after buying an additional 2,277 shares during the period. Finally, Arizona State Retirement System lifted its stake in shares of Stem by 21.7% during the second quarter. Arizona State Retirement System now owns 16,633 shares of the company’s stock worth $119,000 after buying an additional 2,963 shares during the period. 52.42% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently commented on STEM. Northland Securities began coverage on shares of Stem in a research note on Wednesday, September 7th. They set an “outperform” rating and a $24.00 price objective for the company. UBS Group began coverage on shares of Stem in a research note on Tuesday, October 25th. They set a “buy” rating and a $19.00 price objective for the company. Guggenheim set a $17.00 target price on shares of Stem in a report on Thursday, September 29th. Cowen reduced their target price on shares of Stem from $22.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, September 29th. Finally, Cowen reduced their target price on shares of Stem from $22.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, September 29th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Stem presently has a consensus rating of “Moderate Buy” and an average target price of $19.78.

Stem Trading Up 3.8 %

STEM opened at $13.27 on Friday. Stem, Inc. has a fifty-two week low of $5.72 and a fifty-two week high of $22.25. The company has a quick ratio of 2.11, a current ratio of 2.23 and a debt-to-equity ratio of 0.78. The company has a fifty day moving average of $13.32 and a two-hundred day moving average of $11.42.

Stem (NYSE:STEMGet Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.07). Stem had a negative net margin of 47.19% and a negative return on equity of 21.30%. The firm had revenue of $99.50 million during the quarter, compared to analysts’ expectations of $89.81 million. As a group, analysts forecast that Stem, Inc. will post -0.75 EPS for the current fiscal year.

Insider Buying and Selling at Stem

In other Stem news, insider Kim Homenock sold 26,702 shares of Stem stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $17.05, for a total value of $455,269.10. Following the completion of the transaction, the insider now owns 26,702 shares of the company’s stock, valued at $455,269.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Anil Tammineedi sold 100,000 shares of the business’s stock in a transaction dated Friday, September 9th. The shares were sold at an average price of $16.38, for a total transaction of $1,638,000.00. Following the completion of the sale, the director now owns 4,289,849 shares of the company’s stock, valued at $70,267,726.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kim Homenock sold 26,702 shares of the business’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $17.05, for a total transaction of $455,269.10. Following the sale, the insider now directly owns 26,702 shares of the company’s stock, valued at approximately $455,269.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 429,912 shares of company stock valued at $6,520,950. Corporate insiders own 7.20% of the company’s stock.

About Stem

(Get Rating)

Stem, Inc operates as a digitally connected and intelligent energy storage network provider in the United States and internationally. It offers energy storage systems sourced from original equipment manufacturers (OEMs). The company also provides Athena, an artificial intelligence platform, which offers battery hardware and software-enabled services to operate the energy storage systems.

Further Reading

Institutional Ownership by Quarter for Stem (NYSE:STEM)

Receive News & Ratings for Stem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stem and related companies with MarketBeat.com's FREE daily email newsletter.